Uncategorized

On Friday, October 2, 2026, the sarcoma community gathered at CHU Sainte-Justine for the first Journée québécoise sur les sarcomes – Édition des familles (Quebec Sarcoma Day – Family Edition), spearheaded by the Dania Kayali Foundation. The event brought together approximately 100 participants, including patients, family members, healthcare professionals, clinicians, researchers, and institutional representatives, with a shared goal: to provide information, support, and meaningful connections for those affected by sarcoma. Throughout the day, presentations and discussions addressed important aspects of the patient journey, including receiving a diagnosis, rehabilitation, supportive care, advances in sarcoma research, and complementary approaches to well-being. The event also provided a welcoming space for participants to share experiences, discover helpful resources, and connect with others who understand the challenges of living with sarcoma. SaRC-Q was proud to participate in this important initiative and present its resources to patients and their families. Through its website and educational initiatives, the Sarcoma Research Consortium of Quebec (SaRC-Q) aims to make reliable information more accessible, help patients better understand their diagnosis and treatment options, and connect them with relevant resources and support. Engaging directly with patients and their loved ones is an important part of our commitment to building a more informed, connected, and patient-centered sarcoma community across Quebec. At SaRC-Q, we believe that advancing sarcoma care requires more than research and collaboration among healthcare professionals. It also means listening to patients, addressing their needs, and ensuring that they and their families have access to the information and support they need throughout their journey. We extend our sincere thanks to the Dania Kayali Foundation for spearheading this initiative, as well as to CHU Sainte-Justine, the speakers, healthcare teams, and everyone who contributed to making this first edition a meaningful day of learning, connection, and solidarity. Together, we continue to strengthen collaboration, empower patients and families, and advance sarcoma research and care across Quebec.

The Quebec Pediatric and Young Adult Sarcoma Day will take place on October 2, 2026, from 8:00 a.m. to 7:00 p.m. The day will bring together patients, families, healthcare professionals, researchers, and community partners for a day focused on the sarcoma patient journey, treatments, research, and advances in the field. SaRC-Q will be present and involved throughout the day, and we are pleased to support this opportunity to bring the sarcoma community together. Registration is free: https://event.fourwaves.com/fr/sarcomes2026 We look forward to seeing you there!

SaRC-Q is pleased to announce the upcoming opening of the Phase I clinical trial EMBOLD Sarcoma-202 (GSK300640), evaluating risvutatug rezetecan (Ris-Rez/HS-20093), a fully human IgG1 monoclonal antibody targeting B7-H3. The study is expected to open at our site on June 16, 2026, and we are anticipated to be the first site worldwide to activate this trial. This study is particularly encouraging, as the treatment has already demonstrated promising activity in patients with sarcoma in earlier studies conducted primarily in Asia. This North American study is part of the ongoing regulatory development required by agencies such as the FDA and Health Canada. Enrollment will be highly competitive globally: Eligible soft tissue sarcoma histologies include: Excluded histologies: For osteosarcoma, enrollment will proceed in global cohorts of three patients, with dose reassessment after each cohort. We encourage referring physicians to send potentially eligible patients as early as possible to allow timely eligibility assessment and maximize the chance of enrollment. SaRC-Q remains committed to improving access to clinical trials across Quebec. For patients living outside Montreal, our team can assist with accommodation and explore options to support travel expenses. We believe this represents an important opportunity for patients with sarcoma, particularly in the current context of limited access to ifosfamide. For any questions or potential referrals, please contact our team.

At SaRC-Q, we are continually inspired by the strength, resilience, and solidarity shown within the sarcoma community. A recent article published by La Voix de l’Est highlights the inspiring story of Michèle Ashton, who will cross a European lake in support of her friend, Brigitte Beauchamp, who is living with sarcoma. This remarkable initiative reflects the compassion, courage, and unwavering support that so many patients, families, and loved ones demonstrate every day. Stories like Michèle and Brigitte’s remind us of the profound impact that friendship and community can have throughout the cancer journey. At SaRC-Q, we remain committed to advancing awareness, research, patient support, and collaboration for individuals affected by sarcomas across Quebec and beyond. We send our support and encouragement to all those facing the realities of sarcoma. Read the full article here:Elle traverse un lac pour son amie atteinte d’un cancer rare

SaRC-Q had the privilege of attending the Gala Annuel de l’Espoir organized by the Dania Kayali Foundation, an inspiring evening dedicated to raising awareness and support for the sarcoma community. Members of the SaRC-Q Board were invited to share presentations highlighting the realities of sarcoma, the importance of clinical research, and the need to continue advancing collaboration, education, and access to innovative treatments for patients across Quebec and Canada. We sincerely thank the Dania Kayali Foundation for its warm invitation, its commitment to the sarcoma community, and its continued efforts to support patients, families, and research initiatives.

The Sarcoma Research Consortium of Quebec was honoured to participate in a special event held at Champlain College Lennoxville, featuring an inspiring presentation by Patrick Qi Wang, orthopedic oncologist and proud Champlain alumnus. Dr. Wang delivered an engaging talk on the evolution of sarcoma treatment, the challenges currently faced in research, and the importance of collaboration in advancing innovation and patient care. His journey and dedication to sarcoma research served as an inspiration to students and attendees. During the event, the Champlain Student Association presented a $4,000 donation to SaRC-Q. The funds were raised through the Sarcoma Games organized earlier this year by the student community. SaRC-Q sincerely thanks the Champlain community for their generosity and continued commitment to supporting sarcoma research.

We are pleased to announce the launch of StrateGIST 3, a randomized, multicenter, open-label Phase III study evaluating IDRX-42 (GSK6042981) versus sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) following prior treatment with imatinib. About the Study Gastrointestinal stromal tumors are the most common type of soft tissue sarcoma of the gastrointestinal tract. Although imatinib remains the standard first-line therapy, many patients eventually experience disease progression, underscoring the need for additional therapeutic strategies.StrateGIST 3 is designed to compare the efficacy and safety of IDRX-42 with sunitinib, the current standard second-line treatment option. The study is being conducted across multiple centers. Who Can Participate? Patients who meet eligibility criteria may have the opportunity to participate in this important research initiative. Why Join? For further details regarding eligibility, study sites, or referral information, please contact our team. Let’s advance the future of GIST treatment together!

We are thrilled to share the great success of the Champlain-Lennoxville Pink Games Fundraiser, which raised an outstanding $8,000 for SaRC-Q. This remarkable achievement highlights the power of community and collective effort in supporting vital cancer research. The annual Pink Games brought together the Champlain Students’ Association, the Cougars Athletics teams, and many other dedicated members of the Champlain-Lennoxville community. Their enthusiasm and determination not only made this year’s event a success but also doubled the amount raised in 2023. The funds raised will contribute significantly to advancing sarcoma cancer research and providing much-needed support to individuals and families affected by this rare disease. At SaRC-Q, we believe that initiatives like these are pivotal in raising awareness and driving meaningful progress in the fight against sarcoma. We extend our heartfelt thanks and congratulations to the Champlain Students’ Association, the Cougars Athletics teams, and everyone who participated in or contributed to this inspiring fundraiser. Your dedication and generosity inspire us to continue our mission to improve lives through research and innovation. Thank you for making a difference. Together, we are stronger.

We are thrilled to announce that a Phase III, multicenter, randomized, double-blind clinical study is now open for recruitment. This trial focuses on assessing the safety and efficacy of Emactuzumab, a promising investigational therapy, compared to a placebo in patients diagnosed with Tenosynovial Giant Cell Tumor (TGCT). About the Study TGCT, also known as Tumeur à Cellules Géantes de la Gaine Synoviale (TCGGS) in French, is a rare and potentially debilitating condition. This trial aims to explore a new therapeutic option that could significantly improve outcomes for patients. Who Can Participate? We are looking for individuals diagnosed with TGCT who meet the eligibility criteria. This is a unique opportunity to contribute to advancing medical research and potentially benefit from cutting-edge treatment. Why Join? How to Get Involved If you or someone you know is living with TGCT, visit our dedicated trial page to learn more about the study, eligibility requirements, and how to participate. Let’s advance the future of TGCT treatment together!

We’re excited to announce that a new Phase III clinical trial is now open for recruitment. This study is focused on patients with advanced gastrointestinal stromal tumors (GIST) who have previously been treated with Imatinib. Study Overview: This important research seeks to provide valuable insights into new treatment options for advanced GIST, a condition that can be challenging to manage. If you or someone you know is eligible and interested in participating, please reach out for more details. Stay tuned for updates on this promising study and its progress!